Jump to ContentJump to Main Navigation
Show Summary Details

Journal of Perinatal Medicine

Official Journal of the World Association of Perinatal Medicine

Editor-in-Chief: Dudenhausen, Joachim W.

Editorial Board Member: / Bancalari, Eduardo / Greenough, Anne / Genc, Mehmet R. / Chervenak, Frank A. / Chappelle, Joseph / Bergmann, Renate L. / Bernardes, J.F. / Bevilacqua, G. / Blickstein, Isaac / Cabero Roura, Luis / Carbonell-Estrany, Xavier / Carrera, Jose M. / D`Addario, Vincenzo / D'Alton, MD, Mary E. / Dimitrou, G. / Grunebaum, Amos / Hentschel, Roland / Köpcke, W. / Kawabata, Ichiro / Keirse, Marc J.N.C. / Kurjak M.D., Asim / Lee, Ben H. / Levene, Malcolm / Lockwood, Charles J. / Marsal, Karel / Makatsariya, Alexander / Nishida, Hiroshi / Ogata, Edward / Papp, Zoltán / Pejaver, Ranjan Kumar / Pooh, Ritsuko K. / Romero, Roberto / Saugstad, Ola D. / Schenker, Joseph G. / Sen, Cihat / Seri, Istvan / Vetter, Klaus / Winn, Hung N. / Young, Bruce K. / Zimmermann, Roland

IMPACT FACTOR increased in 2015: 1.798
Rank 46 out of 120 in category Pediatrics in the 2015 Thomson Reuters Journal Citation Report/Science Edition

SCImago Journal Rank (SJR) 2014: 0.731
Source Normalized Impact per Paper (SNIP) 2014: 0.687
Impact per Publication (IPP) 2014: 1.483

99,00 € / $149.00 / £75.00*

See all formats and pricing


Select Volume and Issue


Erythropoietin and prematurity – where do we stand?

Xavier Carbonell-Estrany1 / Josep Figueras-Aloy2 / Enriqueta Alvarez3




Corresponding author: Xavier Carbonell-Estrany, MD, PhD Institut Clínic de Ginecologia Obstetricia i Neonatologia Sabino Arana 1 E-08028 Barcelona Spain. Tel.: +34-93-2275607 Fax: +34-93-2275605,

Citation Information: Journal of Perinatal Medicine. Volume 33, Issue 4, Pages 277–286, ISSN (Online) 1619-3997, ISSN (Print) 0300-5577, DOI: 10.1515/JPM.2005.054, August 2005

Publication History

Published Online:


Erythropoietin (EPO) treatment for anemia of prematurity is still controversial. Large multicentric trials demonstrate that administration of EPO+Fe cannot prevent early transfusions, particularly in very low birth weight newborns and in infants with severe neonatal diseases, but may have some beneficial effect to prevent late transfusions. Current treatment of anemia of prematurity should be multifactorial trying to minimize all causes that reduce erthrocytic mass (phlebotomies, use of noninvasive procedures) and promoting all factors that increase it (placental transfusion, adequate nutrition support). To evaluate the real impact of EPO treatment it is mandatory to follow similar transfusion protocols for preterm infants in all the studies. The aim of EPO+Fe administration should be to avoid new late transfusions in very low birth weight preterm infants or to prevent the first transfusion after the second week of life in less immature premature with the objective of reducing the number of donors rather than the number of transfusions. We have limited the use of EPO+Fe to infants <30 weeks gestational age and birth weight ≤1250 g as well as to infants weighing 1250–1500 g with initial severe disease. The comparison of outcomes before (28 months period with EPO+Fe treatment to all premature ≤32 weeks gestational age) and after 20 months of implementation of the new protocol showed a significant decrease in EPO+Fe treatment candidates (40.3% vs. 85.9%, P<0.001) without changes in the percentage of transfusions in both periods. Therefore if EPO treatment is to be given it should be limited to preterm infants with a birth weight <1000 g or those of 1000–1250 g associated with risk factors for blood transfusion. It should be started at 3–7 days of life at doses of 250 U/kg subcutaneously, three times a week, for 4–6 weeks depending on gestational age with oral iron 2–12 mg/kg/day to keep ferritin levels greater than 100 ng/mL.

Keywords: Anemia; blood transfusion; erythropoietin; prematurity

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

Olivia Ballard and Ardythe L. Morrow
Pediatric Clinics of North America, 2013, Volume 60, Number 1, Page 49
E. Álvarez Domínguez, J.M. Pérez Fernández, J. Figueras Aloy, and X. Carbonell Estrany
Anales de Pediatría, 2010, Volume 73, Number 6, Page 334
Raghavendra Rao and Michael K. Georgieff
Clinics in Perinatology, 2009, Volume 36, Number 1, Page 27
M Á Vázquez López, M Á Llamas, R Galera, A R Sanchez, F Lendinez, M Gonzalez-Ripoll, J Díez, and A Bonillo
Journal of Perinatology, 2011, Volume 31, Number 2, Page 118
Pascal E. Sanchez, Fabrice P. Navarro, Raafat P. Fares, Jérémie Nadam, Béatrice Georges, Colette Moulin, Marion Le Cavorsin, Chantal Bonnet, Philippe Ryvlin, Amor Belmeguenai, Jacques Bodennec, Anne Morales, and Laurent Bezin
The Journal of Comparative Neurology, 2009, Volume 514, Number 4, Page 403
N. Haiden
Monatsschrift Kinderheilkunde, 2007, Volume 155, Number 12, Page 1131

Comments (0)

Please log in or register to comment.